Loading
A phase 3 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06956170 by GlaxoSmithKline, with 21 participants enrolled, started 2022-02-10 and due to reach its primary completion in 2024-05-27. Interventions recorded: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
21 enrolled.
The median and upper limit of 95% Confidence Interval were not estimable due to an insufficient number of participants with events within the length of follow-…; Figures from the ClinicalTrials.gov results section (first posted 2025-06-11), not from a publication · 95% CI 1.9 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS)primary | Belantamab Mafodotin+Pomalidomide+Dexamethasone | 10 | The median and upper limit of 95% Confidence Interval were not estimable due to an insufficient number of participants with events within the length of follow-…; Figures from the ClinicalTrials.gov results section (first posted 2025-06-11), not from a publication | 0.53 (0.1 to 2.78) | - | link |
| Bortezomib + Pomalidomide + Dexamethasone | 11 | 14.8 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belantamab mafodotin, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, GSK.
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/